Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onureg and Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes
NCT05782127Phase 2Active, not recruiting
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in myelodysplastic syndrome (MDS), sponsored by Groupe Français des Myélodysplasies. Primary endpoints: Dose-Limiting Toxicity at 28 days and Overall Response at 28 days. Started Dec 2023; status: active, not recruiting.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05782127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05782127.